Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACTIVELLA vs BIMZELX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of estradiol, an estrogen, and norethindrone acetate, a progestin. Estrogens act by binding to nuclear estrogen receptors (ERα and ERβ), which then interact with estrogen response elements on DNA, leading to changes in gene expression that regulate growth, differentiation, and function of female reproductive tissues and other tissues. Norethindrone acetate is a progestin that induces secretory changes in the endometrium, reducing the risk of endometrial hyperplasia and carcinoma associated with unopposed estrogen therapy.
BIMZELX (bimekizumab) is a humanized monoclonal Ig G1 antibody that selectively neutralizes interleukin-17A (IL-17A) and interleukin-17F (IL-17F), inhibiting their binding to the IL-17 receptor and subsequent pro-inflammatory signaling.
Treatment of moderate to severe vasomotor symptoms associated with menopause,Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with menopause,Prevention of postmenopausal osteoporosis
Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy,Active psoriatic arthritis in adults,Active ankylosing spondylitis in adults
One tablet (1 mg estradiol + 0.5 mg norethindrone acetate) orally once daily, continuously.
Subcutaneous injection: 160 mg (two 80 mg injections) at week 0, week 2, week 4, then every 4 weeks.
Estradiol has a terminal half-life of approximately 12–14 hours following transdermal administration. Norethindrone has a terminal half-life of approximately 8–10 hours. The combined product achieves steady-state within 3–5 days.
Terminal elimination half-life is approximately 26 days (range 22–29 days) across approved doses; supports every 4-week subcutaneous dosing.
Estradiol is metabolized primarily in the liver via CYP3A4 and other CYPs, as well as by 17β-hydroxysteroid dehydrogenase and sulfotransferases. Norethindrone acetate is metabolized in the liver, primarily via reduction and conjugation, with CYP3A4 involved in some oxidative metabolism.
Bimekizumab is likely degraded into small peptides and amino acids via general protein catabolism. It is not metabolized by CYP450 enzymes.
Estradiol is primarily excreted in urine (∼50%) as glucuronide and sulfate conjugates, with ∼30% excreted in feces via biliary elimination. Norethindrone is excreted mainly in urine (∼60%) as metabolites, with ∼40% in feces.
Bimekizumab is a monoclonal antibody that is degraded into small peptides and amino acids via general protein catabolism; no renal or biliary excretion of intact antibody. Fecal excretion of degraded fragments is minor (<1%).
Estradiol is ∼98% bound to sex hormone-binding globulin (SHBG) and albumin. Norethindrone is ∼95–97% bound to SHBG and albumin.
Approximately 99% bound to target (IL-17A and IL-17F) in serum; albumin binding is negligible.
Estradiol has an apparent volume of distribution (Vd) of approximately 1.2 L/kg, indicating extensive distribution into tissues. Norethindrone has a Vd of approximately 3–5 L/kg, indicating wide distribution.
Volume of distribution at steady state is approximately 7.0 L (0.1 L/kg assuming 70 kg), indicating limited extravascular distribution, consistent with a monoclonal antibody primarily in plasma and interstitial fluid.
Transdermal estradiol has a bioavailability of approximately 10% relative to oral administration due to avoidance of first-pass metabolism. Oral norethindrone acetate has a bioavailability of approximately 50–60%.
Subcutaneous: Approximately 80% (range 60–100%) compared to intravenous administration.
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (Cr Cl <30 m L/min); use contraindicated.
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (e GFR <30 m L/min/1.73 m2).
Contraindicated in severe hepatic disease (Child-Pugh class C). For mild to moderate impairment (Child-Pugh A or B), use caution and monitor; no specific dose adjustment established.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C).
Not indicated for use in pediatric patients; safety and efficacy not established.
Safety and efficacy not established in pediatric patients.
Start with the lowest effective dose; monitor for thromboembolic events and cognitive effects. No specific dose adjustment required, but consider age-related renal and hepatic decline.
No specific dose adjustment recommended; pharmacokinetics similar to younger adults in clinical studies with patients up to 75 years.
Estrogens increase the risk of endometrial cancer. There is an increased risk of cardiovascular events, breast cancer, and probable dementia with estrogen plus progestin therapy. Actively monitor for these events.
None.
Cardiovascular disorders: Increased risks of stroke, myocardial infarction, and venous thromboembolism (VTE).,Malignancy: Increased risk of breast cancer, endometrial cancer, and ovarian cancer.,Probable dementia: Increased risk in women aged 65 years or older.,Gallbladder disease, hypertriglyceridemia, fluid retention, hypocalcemia, and hereditary angioedema.,Retinal thrombosis: Discontinue if sudden vision loss occurs.,Laboratory tests: May alter thyroid function tests, coagulation tests, and glucose tolerance.
Increased risk of infections, including serious infections; avoid use during active infection,Hypersensitivity reactions including urticaria and angioedema,Exacerbation of inflammatory bowel disease (Crohn's disease or ulcerative colitis),Potential for increased suicidality or depression; monitor for neuropsychiatric symptoms,Avoid live vaccines during treatment,Tuberculosis screening prior to initiation
Undiagnosed abnormal genital bleeding,Known, suspected, or history of breast cancer,Known or suspected estrogen-dependent neoplasia,Active or past history of venous thromboembolism (VTE) or arterial thromboembolism (ATE),Current or recent (within 1 year) VTE or ATE,Known thrombophilic disorders (e.g., protein C, S, or antithrombin deficiency; factor V Leiden mutation),Active or past history of arterial thromboembolic disease (e.g., stroke, MI),Known liver impairment or disease,Known or suspected pregnancy,Hypersensitivity to any component of the product
Known hypersensitivity to bimekizumab or any excipient,Active tuberculosis or other severe infections
Grapefruit juice may increase estrogen levels by inhibiting CYP3A4; avoid excessive consumption. High-fat meals can increase absorption of oral estrogens; take consistently with or without food to maintain steady levels.
There are no known food interactions with BIMZELX. Take with or without food.
Pregnancy Category X. Estrogen and progestin exposure during the first trimester is associated with congenital anomalies including cardiovascular and limb defects. Use during the second and third trimesters is contraindicated due to risk of fetal genital abnormalities and potential long-term neurodevelopmental effects. Avoid in pregnancy.
Bimekizumab is a humanized monoclonal Ig G1 antibody that inhibits IL-17A and IL-17F. As a large protein, it is transported across the placenta via Fc Rn-mediated transfer, with fetal levels increasing during the second and third trimesters. Available data are insufficient to determine a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Animal studies showed no evidence of teratogenicity or fetal harm in monkeys at doses up to 100 mg/kg (approximately 30 times the human exposure at the recommended dose). However, monoclonal antibodies are known to cross the placenta, and the theoretical risk of fetal immune suppression exists. Therefore, bimekizumab should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Estradiol and norethindrone acetate are excreted into breast milk. Estradiol M/P ratio approximately 0.5; norethindrone M/P ratio approximately 0.4. May reduce milk production and alter composition. Use during breastfeeding is not recommended.
It is unknown whether bimekizumab is excreted in human milk or absorbed systemically after ingestion. Monoclonal antibodies are generally present in breast milk at very low concentrations with limited oral bioavailability due to protein digestion in the infant's gastrointestinal tract. The M/P ratio has not been determined. Due to the potential for adverse reactions in the breastfed infant, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Not applicable; contraindicated in pregnancy.
No dose adjustment is recommended during pregnancy based on pharmacokinetic changes. Bimekizumab clearance is not expected to be significantly altered by pregnancy-related physiological changes. However, given the limited data, the drug should be used only if clearly needed. Monitor clinical response and adjust dose if necessary (though no standard guidelines exist).
For patients with an intact uterus, estrogen must be combined with a progestogen (norethindrone acetate) to prevent endometrial hyperplasia. Initiate at the lowest effective dose for the shortest duration. Avoid in women with active thromboembolic disease, known or suspected breast cancer, or undiagnosed abnormal genital bleeding. Consider transdermal route if oral absorption is compromised or for migraine with aura.
BIMZELX (bimekizumab) is a humanized monoclonal Ig G1 antibody that selectively inhibits both IL-17A and IL-17F. It is administered subcutaneously with a loading dose at weeks 0, 2, 4, then every 8 weeks. Monitor for exacerbations of inflammatory bowel disease (Crohn's or ulcerative colitis) as IL-17 inhibition can rarely trigger or worsen these conditions. Do not administer live vaccines during treatment. Consider tuberculosis screening prior to initiation.
Take this medication exactly as prescribed; do not skip doses or stop without consulting your doctor.,Report any unusual vaginal bleeding, breast lumps, or symptoms of blood clots (e.g., leg pain, chest pain, sudden shortness of breath, vision changes) immediately.,Smoking increases the risk of cardiovascular side effects, especially in women over 35; avoid smoking while on this therapy.,This medication does not protect against sexually transmitted infections or HIV.,Regular medical check-ups, including breast exams and mammograms, are essential during therapy.
You may be at increased risk of infections, including upper respiratory tract infections and oral candidiasis. Report any signs of infection to your healthcare provider promptly.,If you have a history of inflammatory bowel disease (Crohn's disease or ulcerative colitis), tell your doctor before starting treatment, as this medicine can worsen it.,Do not receive live vaccines while on BIMZELX. Discuss any required vaccinations with your doctor before starting therapy.,This medication is given as an injection under the skin. You or your caregiver can be trained to administer it at home. Rotate injection sites and do not inject into tender, bruised, or scarred skin.,Store BIMZELX in the refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light. Keep in original carton until use.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACTIVELLA vs BIMZELX, answered by our medical review team.
ACTIVELLA is a Estrogen/Progestin Combination that works by Combination of estradiol, an estrogen, and norethindrone acetate, a progestin. Estrogens act by binding to nuclear estrogen receptors (ERα and ERβ), which then interact with estrogen response elements on DNA, leading to changes in gene expression that regulate growth, differentiation, and function of female reproductive tissues and other tissues. Norethindrone acetate is a progestin that induces secretory changes in the endometrium, reducing the risk of endometrial hyperplasia and carcinoma associated with unopposed estrogen therapy.. BIMZELX is a Prostaglandin Analog that works by BIMZELX (bimekizumab) is a humanized monoclonal Ig G1 antibody that selectively neutralizes interleukin-17A (IL-17A) and interleukin-17F (IL-17F), inhibiting their binding to the IL-17 receptor and subsequent pro-inflammatory signaling.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACTIVELLA and BIMZELX depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACTIVELLA is: One tablet (1 mg estradiol + 0.5 mg norethindrone acetate) orally once daily, continuously.. The standard adult dose of BIMZELX is: Subcutaneous injection: 160 mg (two 80 mg injections) at week 0, week 2, week 4, then every 4 weeks.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACTIVELLA and BIMZELX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACTIVELLA is classified as Category C. Pregnancy Category X. Estrogen and progestin exposure during the first trimester is associated with congenital anomalies including cardiovascular and limb defects. Use during the s. BIMZELX is classified as Category C. Bimekizumab is a humanized monoclonal IgG1 antibody that inhibits IL-17A and IL-17F. As a large protein, it is transported across the placenta via FcRn-mediated transfer, with feta. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.